Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1981 Dec;68(6):1592–1596. doi: 10.1172/JCI110414

Apolipoprotein C-III-1 activates lysosomal sphingomyelinase in vitro.

A J Alpert, A L Beaudet
PMCID: PMC370964  PMID: 6274912

Abstract

Apolipoprotein (apo)C-III-1 from human very low density lipoprotein stimulates 14-fold the activity of lysosomal sphingomyelinase from human fibroblasts. At the sphingomyelin concentrations tested, maximal stimulation was obtained with 5 microM apoC-III-1 or apoC mixture. Apolipoproteins A-I, A-II, B, and C-I conferred little or no stimulation. Sphingomyelinase was stimulated 20-fold by lysophosphatidylcholine with an optimum concentration of 70 microM using 0.3 mM substrate. Sphingomyelinase activity was inhibited by concentrations of apoC-III-1 and lysophosphatidylcholine three- to fivefold above stimulatory levels. Triton X-100 activated sphingomyelinase 300-fold with a pH optimum of 5.0, while the pH optimum with the biological activators was 4.0. These results raise the possibility of an in vivo activity for the biological activators. The proteins that enter lysosomes as part of a lipoprotein complex may activate lysosomal enzymes that degrade the lipid components.

Full text

PDF
1592

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baraton G., Revol A. Activateur des sphinhgohydrolases et nature du déficit en sphingomyélinase dans la maladie de Niemann-Pick type A, B et C. Clin Chim Acta. 1977 May 2;76(3):339–343. doi: 10.1016/0009-8981(77)90160-7. [DOI] [PubMed] [Google Scholar]
  2. Beaudet A. L., Lipson M. H., Ferry G. D., Nichols B. L., Jr Acid lipase in cultured fibroblasts: cholesterol ester storage disease. J Lab Clin Med. 1974 Jul;84(1):54–61. [PubMed] [Google Scholar]
  3. Breckenridge W. C., Little J. A., Steiner G., Chow A., Poapst M. Hypertriglyceridemia associated with deficiency of apolipoprotein C-II. N Engl J Med. 1978 Jun 8;298(23):1265–1273. doi: 10.1056/NEJM197806082982301. [DOI] [PubMed] [Google Scholar]
  4. Brown M. S., Dana S. E., Goldstein J. L. Receptor-dependent hydrolysis of cholesteryl esters contained in plasma low density lipoprotein. Proc Natl Acad Sci U S A. 1975 Aug;72(8):2925–2929. doi: 10.1073/pnas.72.8.2925. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brown W. V., Levy R. I., Fredrickson D. S. Studies of the proteins in human plasma very low density lipoproteins. J Biol Chem. 1969 Oct 25;244(20):5687–5694. [PubMed] [Google Scholar]
  6. Conzelmann E., Sandhoff K. AB variant of infantile GM2 gangliosidosis: deficiency of a factor necessary for stimulation of hexosaminidase A-catalyzed degradation of ganglioside GM2 and glycolipid GA2. Proc Natl Acad Sci U S A. 1978 Aug;75(8):3979–3983. doi: 10.1073/pnas.75.8.3979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Ekman R., Nilsson-Ehle P. Effects of apolipoproteins on lipoprotein lipase activity of human adipose tissue. Clin Chim Acta. 1975 Aug 18;63(1):29–35. doi: 10.1016/0009-8981(75)90374-5. [DOI] [PubMed] [Google Scholar]
  8. Fischer G., Jatzkewitz H. The activator of cerebroside sulphatase. Binding studies with enzyme and substrate demonstrating the detergent function of the activator protein. Biochim Biophys Acta. 1977 Apr 12;481(2):561–572. doi: 10.1016/0005-2744(77)90288-1. [DOI] [PubMed] [Google Scholar]
  9. Gatt S., Dinur T., Yedgar S., Leibovitz-Ben Gershon Z. Effect of detergents on the utilization of sphingomyelin by brain sphingomyelinases. Adv Exp Med Biol. 1978;101:487–500. doi: 10.1007/978-1-4615-9071-2_44. [DOI] [PubMed] [Google Scholar]
  10. Gatt S. Magnesium-dependent sphingomyelinase. Biochem Biophys Res Commun. 1976 Jan 12;68(1):235–241. doi: 10.1016/0006-291x(76)90034-6. [DOI] [PubMed] [Google Scholar]
  11. HO M. W., Rigby M. Glucocerebrosidase: stoichiometry of association between effector and catalytic proteins. Biochim Biophys Acta. 1975 Jul 27;397(1):267–273. doi: 10.1016/0005-2744(75)90199-0. [DOI] [PubMed] [Google Scholar]
  12. Hechtman P., LeBlanc D. Purification and properties of the hexosaminidase A-activating protein from human liver. Biochem J. 1977 Dec 1;167(3):693–701. doi: 10.1042/bj1670693. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hostetler K. Y., Yazaki P. J. The subcellular localization of neutral sphingomyelinase in rat liver. J Lipid Res. 1979 May;20(4):456–463. [PubMed] [Google Scholar]
  14. Innerarity T. L., Mahley R. W. Enhanced binding by cultured human fibroblasts of apo-E-containing lipoproteins as compared with low density lipoproteins. Biochemistry. 1978 Apr 18;17(8):1440–1447. doi: 10.1021/bi00601a013. [DOI] [PubMed] [Google Scholar]
  15. Kanfer J. N., Young O. M., Shapiro D., Brady R. O. The metabolism of sphingomyelin. I. Purification and properties of a sphingomyelin-cleaving enzyme from rat liver tissue. J Biol Chem. 1966 Mar 10;241(5):1081–1084. [PubMed] [Google Scholar]
  16. Krauss R. M., Herbert P. N., Levy R. I., Fredrickson D. S. Further observations on the activation and inhibition of lipoprotein lipase by apolipoproteins. Circ Res. 1973 Oct;33(4):403–411. doi: 10.1161/01.res.33.4.403. [DOI] [PubMed] [Google Scholar]
  17. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  18. Li S. C., Li Y. T. An activator stimulating the enzymic hydrolysis of sphingoglycolipids. J Biol Chem. 1976 Feb 25;251(4):1159–1163. [PubMed] [Google Scholar]
  19. Morris D. A., McNeil R., Castellino F. J., Thomas J. K. Interaction of lysophosphatidylcholine with phosphatidylcholine bilayers. A photo-physical and NMR study. Biochim Biophys Acta. 1980 Jul;599(2):380–390. doi: 10.1016/0005-2736(80)90185-6. [DOI] [PubMed] [Google Scholar]
  20. Mraz W., Fischer G., Jatzkewitz H. Low molecular weight proteins in secondary lysosomes as activators of different sphingolipid hydrolases. FEBS Lett. 1976 Aug 1;67(1):104–109. doi: 10.1016/0014-5793(76)80879-4. [DOI] [PubMed] [Google Scholar]
  21. Rao B. G., Spence M. W. Sphingomyelinase activity at pH 7.4 in human brain and a comparison to activity at pH 5.0. J Lipid Res. 1976 Sep;17(5):506–515. [PubMed] [Google Scholar]
  22. Scanu A., Toth J., Edelstein C., Koga S., Stiller E. Fractionation of human serum high density lipoprotein in urea solutions. Evidence for polypeptide heterogeneity. Biochemistry. 1969 Aug;8(8):3309–3316. doi: 10.1021/bi00836a027. [DOI] [PubMed] [Google Scholar]
  23. Shelburne F., Hanks J., Meyers W., Quarfordt S. Effect of apoproteins on hepatic uptake of triglyceride emulsions in the rat. J Clin Invest. 1980 Mar;65(3):652–658. doi: 10.1172/JCI109710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Socorro L., Camejo G. Preparation and properties of soluble, immunoreactive apoLDL. J Lipid Res. 1979 Jul;20(5):631–638. [PubMed] [Google Scholar]
  25. Soutar A. K., Garner C. W., Baker H. N., Sparrow J. T., Jackson R. L., Gotto A. M., Smith L. C. Effect of the human plasma apolipoproteins and phosphatidylcholine acyl donor on the activity of lecithin: cholesterol acyltransferase. Biochemistry. 1975 Jul 15;14(14):3057–3064. doi: 10.1021/bi00685a003. [DOI] [PubMed] [Google Scholar]
  26. Yamaguchi S., Suzuki K. A novel magnesium-independent neutral sphingomyelinase associated with rat central nervous system meylin. J Biol Chem. 1978 Jun 25;253(12):4090–4092. [PubMed] [Google Scholar]
  27. Yamaguchi S., Suzuki K. Purification and characterization of sphingomyelinase from human brain. J Biol Chem. 1977 Jun 10;252(11):3805–3813. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES